Evidence map›Paper›PMID 35008431›Full record

ArticleInternational journal of molecular sciences2021

Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Zachery R Reichert, Tadas Kasputis, Srinivas Nallandhighal, Sophia M Abusamra, Amy Kasputis, Saloni Haruray, Yugang Wang, Shamara Williams, Udit Singhal, Ajjai Alva and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Liquid biopsy to personalize treatment for metastatic prostate cancer.American journal of translational research · 2024
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zachery R ReichertDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-0356-8796
Tadas KasputisDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Srinivas NallandhighalDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Sophia M AbusamraDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0001-9588-5005
Amy KasputisDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Saloni HarurayDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-3939-8872
Yugang WangDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Shamara WilliamsDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-6101-6212
Udit SinghalDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-3928-9476
Ajjai AlvaDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Frank C CackowskiDivision of Medical Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.ORCID 0000-0002-0075-3745
Megan E V CaramDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Phillip L PalmbosDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Sarah E YentzDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
David C SmithDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Joshi J AlumkalDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-1278-0166
Todd M MorganDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
NCI NIH HHS P50 CA186786NIH HHS 1R01CA240991Prostate Cancer Foundation YIATaubman Emerging Scholar Award University of Michigan
6 · The paper itself

Abstract

The substantial biological heterogeneity of metastatic prostate cancer has hindered the development of personalized therapeutic approaches. Therefore, it is difficult to predict the course of metastatic hormone-sensitive prostate cancer (mHSPC), with some men remaining on first-line androgen deprivation therapy (ADT) for several years while others progress more rapidly. Improving our ability to risk-stratify patients would allow for the optimization of systemic therapies and support the development of stratified prospective clinical trials focused on patients likely to have the greatest potential benefit. Here, we applied a liquid biopsy approach to identify clinically relevant, blood-based prognostic biomarkers in patients with mHSPC. Gene expression indicating the presence of CTCs was greater in CHAARTED high-volume (HV) patients (52% CTC

Indexed as

Drug Resistance, NeoplasmAndrogen AntagonistsAntigens, NeoplasmBiomarkers, TumorDesmoglein 2Gene Expression ProfilingHumansKallikreinsMaleMidkineMultiplex Polymerase Chain ReactionNeoplastic Cells, CirculatingPrecision MedicinePrognosisProspective StudiesProstate-Specific AntigenAndrogen AntagonistsAntigens, NeoplasmAR protein, humanBiomarkers, TumorDesmoglein 2DSG2 protein, humanKallikreinsKLK3 protein, humanMDK protein, humanMidkineprostate cancer antigen 3, humanProstate-Specific AntigenReceptors, Androgencastration-sensitivecirculating tumor cellsCTCsgene expressionhormone-sensitivemetastaticprognosticprostate cancer

Identifiers

PMID35008431
PMCPMC8744626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.